Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

April 30th 2025

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Linvoseltamab Receives EC Approval for Heavily Pretreated R/R Myeloma

April 28th 2025

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

April 24th 2025

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Joseph on the Research Behind the Role of Exercise and Supportive Care in Myeloma

April 23rd 2025

Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.

Dr Farid on Current and Future Investigations of MDC-CAR-BCMA001 in Myeloma and AL Amyloidosis

April 22nd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses 2 planned investigations of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and AL amyloidosis.

Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma

April 22nd 2025

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Dr Bishop on the Rationale for Evaluating Anito-Cel in R/R Myeloma

April 21st 2025

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Dr Zonder on the Importance of Early Screening for Myeloma Among High-Risk Patients

April 18th 2025

Jeffrey Zonder, MD, discusses the need for increased screening for patients who are at higher risk of developing multiple myeloma.

Dr Richardson on the Role of Quadruplet Regimens in Newly Diagnosed Myeloma

April 17th 2025

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

April 17th 2025

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Dr Farid on the Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 16th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Dr Richter on Early Abnormalities Indicative of a Multiple Myeloma Diagnosis

April 15th 2025

Joshua Richter, MD, discusses the identification of early abnormalities that may indicate that a patient has multiple myeloma.

Dr Mateos on the Future Clinical Development of Cilta-Cel in Myeloma

April 15th 2025

María-Victoria Mateos, MD, PhD, discusses the future clinical development of ciltacabtagene autoleucel in multiple myeloma.

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

April 14th 2025

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

x